[go: up one dir, main page]

MXPA05001275A - 2-amino-benzotiazolsulfonhamida como inhibidores de proteasa de virus de inmunodeficiencia humana de amplio espectro. - Google Patents

2-amino-benzotiazolsulfonhamida como inhibidores de proteasa de virus de inmunodeficiencia humana de amplio espectro.

Info

Publication number
MXPA05001275A
MXPA05001275A MXPA05001275A MXPA05001275A MXPA05001275A MX PA05001275 A MXPA05001275 A MX PA05001275A MX PA05001275 A MXPA05001275 A MX PA05001275A MX PA05001275 A MXPA05001275 A MX PA05001275A MX PA05001275 A MXPA05001275 A MX PA05001275A
Authority
MX
Mexico
Prior art keywords
amino
hiv protease
6alkyl
hydrogen
broadspectrum
Prior art date
Application number
MXPA05001275A
Other languages
English (en)
Inventor
Daniel P Getman
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MXPA05001275A publication Critical patent/MXPA05001275A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invencion se refiere al uso de 2-amino-benzotiazoles, que tienen la formula en donde R1 es hexahidrofuro[2,3-b]furanilo, tetrahidrofuranilo, oxazolilo, tiazolilo, piridinilo o fenilo opcionalmente sustituido con uno o mas sustituyentes independientemente seleccionados de alquilo de C1-6, hidroxi, amino, halogeno, amino-alquilo de C1-4 y mono-o di(alquilo de C1-4)amino; R2 es hidrogeno o alquilo de C1-6 L es un enlace directo, -O-, alcanodiilo de C1-6-O- o -0-alcanodiilo de C1-6 R3 es fenilo-alquilo de C1-4 R4 es alquilo de C1-6 R5 es hidrogeno o alquilo de C1-6 R6 es hidrogeno o alquilo de C1-6 en la fabricacion de un medicamento util para inhibir proteasa de VIH mutante en un mamifero infectado con proteasa de VIH mutante; tambien se refiere a compuestos novedosos de la formula (1).
MXPA05001275A 2002-08-02 2003-08-04 2-amino-benzotiazolsulfonhamida como inhibidores de proteasa de virus de inmunodeficiencia humana de amplio espectro. MXPA05001275A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02078231 2002-08-02
US42786202P 2002-11-20 2002-11-20
PCT/EP2003/050359 WO2004014371A1 (en) 2002-08-02 2003-08-04 Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors

Publications (1)

Publication Number Publication Date
MXPA05001275A true MXPA05001275A (es) 2005-04-28

Family

ID=31716850

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05001275A MXPA05001275A (es) 2002-08-02 2003-08-04 2-amino-benzotiazolsulfonhamida como inhibidores de proteasa de virus de inmunodeficiencia humana de amplio espectro.

Country Status (16)

Country Link
US (2) US20050267156A1 (es)
EP (1) EP1545518A1 (es)
KR (1) KR20050025647A (es)
CN (1) CN1671380B (es)
AP (1) AP1878A (es)
AU (1) AU2003262561B2 (es)
BR (1) BR0305717A (es)
CA (1) CA2492832C (es)
EA (1) EA008594B1 (es)
HR (1) HRP20050605A2 (es)
IL (1) IL166257A (es)
MX (1) MXPA05001275A (es)
NO (1) NO20051089L (es)
NZ (1) NZ538488A (es)
PL (1) PL374948A1 (es)
WO (1) WO2004014371A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566340C (en) * 2004-05-07 2014-05-06 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
JO2841B1 (en) * 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
US8267163B2 (en) * 2008-03-17 2012-09-18 Visteon Global Technologies, Inc. Radiator tube dimple pattern
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
CA2802492C (en) 2010-07-02 2018-10-16 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
ES2634490T3 (es) 2010-07-02 2017-09-28 Gilead Sciences, Inc. Derivados de ácido napht-2-ylacetico para tratar el sida
US9024038B2 (en) 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
AP2013007249A0 (en) 2011-04-21 2013-11-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
PH12014500842A1 (en) 2012-04-20 2014-06-09 Gilead Sciences Inc Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DE69415326T2 (de) * 1993-08-24 1999-06-02 G.D. Searle & Co., Chicago, Ill. Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
NZ527391A (en) * 2001-02-14 2005-04-29 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Also Published As

Publication number Publication date
BR0305717A (pt) 2004-09-28
KR20050025647A (ko) 2005-03-14
CN1671380B (zh) 2010-05-26
EA200500298A1 (ru) 2005-08-25
WO2004014371A1 (en) 2004-02-19
US20090203742A1 (en) 2009-08-13
CN1671380A (zh) 2005-09-21
CA2492832C (en) 2012-05-22
AP2005003242A0 (en) 2005-03-31
US20050267156A1 (en) 2005-12-01
NZ538488A (en) 2007-10-26
EA008594B1 (ru) 2007-06-29
AP1878A (en) 2008-08-13
EP1545518A1 (en) 2005-06-29
HRP20050605A2 (en) 2006-02-28
AU2003262561B2 (en) 2008-10-16
NO20051089L (no) 2005-05-02
IL166257A0 (en) 2006-01-15
PL374948A1 (en) 2005-11-14
AU2003262561A1 (en) 2004-02-25
IL166257A (en) 2013-04-30
CA2492832A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
MXPA04004037A (es) Compuestos novedosos de 1, 2, 4-de triazol.
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
BR0210030A (pt) Derivado de fenilpiridinacarbonilpiperazina
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
PL366590A1 (en) Novel compounds as anti-inflammatorz, immunomodulatory and anti-proliferatory agents
GB0305142D0 (en) Synthesis
DK1613304T3 (da) DPP-IV-inhibitorer
MY136789A (en) Metalloproteinase inhibitors
SE0201976D0 (sv) Novel compounds
TW200730540A (en) Novel peptide compounds
WO2005028429A3 (en) Haloalkyl containing compounds as cysteine protease inhibitors
MY129188A (en) Metalloproteinase inhibitors
MXPA05001275A (es) 2-amino-benzotiazolsulfonhamida como inhibidores de proteasa de virus de inmunodeficiencia humana de amplio espectro.
EP1709037B8 (en) Hiv protease inhibiting sulfonamides
TW200626564A (en) Carboxylic acid derivative containing thiazole ring and medical use thereof
IL190024A0 (en) Stabilized protease composition
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
TW200505446A (en) Inhibitor of cox
ATE526323T1 (de) Die hiv-protease hemmende verbindungen
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
TW200606163A (en) Imidazopyridine compound
MXPA04003478A (es) Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales.
WO2006095139A3 (en) Cancer treatment using specific 3,6,9-substituted acridines

Legal Events

Date Code Title Description
FG Grant or registration